Scandinavian Real Heart AB (Publ) (HEART.ST)
SEK 13.6
(-6.21%)
SEK 13.6
(-6.21%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 6.35 Million SEK | 309.13% |
| 2022 | 1.55 Million SEK | -28.57% |
| 2021 | 2.17 Million SEK | -22.22% |
| 2020 | 2.79 Million SEK | -11.07% |
| 2019 | 3.14 Million SEK | -9.34% |
| 2018 | 3.46 Million SEK | -13.33% |
| 2017 | 4 Million SEK | 55.72% |
| 2016 | 2.56 Million SEK | 1686.96% |
| 2015 | 143.75 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 5.87 Million SEK | -7.46% |
| 2024 Q2 | 5.4 Million SEK | -8.07% |
| 2023 Q3 | 7.46 Million SEK | -5.97% |
| 2023 FY | 6.35 Million SEK | 309.13% |
| 2023 Q4 | 6.35 Million SEK | -14.95% |
| 2023 Q1 | 5.19 Million SEK | 234.72% |
| 2023 Q2 | 7.94 Million SEK | 52.83% |
| 2022 Q1 | 2.01 Million SEK | -7.14% |
| 2022 Q2 | 1.86 Million SEK | -7.69% |
| 2022 Q4 | 1.55 Million SEK | -9.09% |
| 2022 Q3 | 1.7 Million SEK | -8.33% |
| 2022 FY | 1.55 Million SEK | -28.57% |
| 2021 Q2 | 2.48 Million SEK | -5.88% |
| 2021 Q1 | 2.63 Million SEK | -5.56% |
| 2021 Q3 | 2.32 Million SEK | -6.25% |
| 2021 Q4 | 2.17 Million SEK | -6.67% |
| 2021 FY | 2.17 Million SEK | -22.22% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 FY | 2.79 Million SEK | -11.07% |
| 2020 Q1 | - SEK | -100.0% |
| 2020 Q4 | 2.79 Million SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 FY | 3.14 Million SEK | -9.34% |
| 2019 Q1 | 3.46 Million SEK | 0.0% |
| 2019 Q2 | - SEK | -100.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q4 | 3.14 Million SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 FY | 3.46 Million SEK | -13.33% |
| 2018 Q4 | 3.46 Million SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 FY | 4 Million SEK | 55.72% |
| 2017 Q3 | - SEK | -100.0% |
| 2017 Q4 | 4 Million SEK | 0.0% |
| 2017 Q2 | 2.53 Million SEK | -0.74% |
| 2017 Q1 | 2.55 Million SEK | 0.0% |
| 2016 Q2 | 2.6 Million SEK | 0.0% |
| 2016 Q4 | - SEK | -100.0% |
| 2016 FY | 2.56 Million SEK | 1686.96% |
| 2016 Q3 | 2.58 Million SEK | -0.72% |
| 2015 Q2 | 181.25 Thousand SEK | -9.38% |
| 2015 FY | 143.75 Thousand SEK | 0.0% |
| 2015 Q4 | 143.75 Thousand SEK | -11.54% |
| 2015 Q3 | 162.5 Thousand SEK | -10.34% |
| 2015 Q1 | 200 Thousand SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.564% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.564% |
| Arcoma AB | 1.92 Million SEK | -229.679% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 84.983% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.638% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 88.99% |
| CellaVision AB (publ) | 28.66 Million SEK | 77.837% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -2748.843% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | -262.403% |
| Duearity AB (publ) | 2.94 Million SEK | -116.086% |
| Dignitana AB (publ) | 6.07 Million SEK | -4.54% |
| Episurf Medical AB (publ) | 2.3 Million SEK | -176.214% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.837% |
| Iconovo AB (publ) | 4.9 Million SEK | -29.469% |
| Integrum AB (publ) | 4.84 Million SEK | -31.135% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -2983.582% |
| Mentice AB (publ) | 2.14 Million SEK | -196.312% |
| OssDsign AB (publ) | 214 Thousand SEK | -2868.654% |
| Paxman AB (publ) | 2.53 Million SEK | -150.905% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | -111.482% |
| SciBase Holding AB (publ) | 4.17 Million SEK | -52.02% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 66.919% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -527.759% |
| Senzime AB (publ) | 8.57 Million SEK | 25.939% |
| SpectraCure AB (publ) | 4.39 Million SEK | -44.483% |
| Stille AB | 38.06 Million SEK | 83.311% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.661% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 69.99% |